TrialNaunyn-Schmiedeberg's archives of pharmacology2026
Phase I randomized double-blind parallel-group study: pharmacokinetics, safety, and immunogenicity of pertuzumab biosimilar SYSA1901 in healthy Chinese males.
Yucai Xu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.